The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
作者: Martin H. VossRupal S. BhattElizabeth R. PlimackBrian I. RiniRobert S. AlterJ. Thaddeus BeckDawn WilsonXiaosha ZhangMusa MutyabaChad GlasserKenneth M. AttieMatthew L. ShermanShuchi S. PandyaMichael B. Atkins
作者单位: 11 Memorial Sloan Kettering Cancer Center, New York, New York.
22 Department of Medicine, Weill Medical College of Cornell University, New York, New York.
33 Beth Israel Deaconess Medical Center, Boston, Massachusetts.
44 Fox Chase Cancer Center, Philadelphia, Pennsylvania.
55 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
66 John Theurer Cancer Center Hackensack UMC, Hackensack, New Jersey.
77 Highlands Oncology Group, Fayetteville, Arkansas.
88 Acceleron Pharma, Cambridge, Massachusetts.
99 Georgetown University Medical Center, Washington, DC.
刊名: Clinical Cancer Research, 2017, Vol.23 (14), pp.3557-3565
来源数据库: Royal Society
DOI: 10.1158/1078-0432.CCR-16-2395
全文获取路径: The Royal Society 
分享到:

×